chrisvoncsefalvay/vaers-outcomes huggingface dataset:
From initial information received at manufacturer on 03/Mar/2003 from manufacturer (HQ6283021Jan2003) concerning events occurring in the U.S., it was reported that a male patient received ACTHIB and IPOL, lot numbers and site/route are not reported. ACTHIB was given on 23/Jul/2001 and on 11/Jan/2002. IPOL was given on 28/Feb/2001, 28/Apr/2001 and on 23/Jul/2001. The patient experienced symptoms of speech, language and social delay- the onset date and time of these reactions are unknown. Patient's outcome is unknown. Other vaccine information not provided.
as soon patient received the vaccine he complained of nausea, dizziness and hot. I asked the patient has he eaten and drink anything prior to receiving the vaccine. patient states he has not eaten since yesterday morning. I gave him turkey sandwich, Hersey's chocolate to eat and he drink sprite, 10 minutes later patient was fine. I kept the patient for 45 minutes to make sure he was ok before going home. The patient left with his sister
Approximately 2 hours after DTap and IPV was given, the patient developed head to toe dark red, itchy rash. This lasted approximately 3 to 4 days. The patient was treated with Benadryl per local pediatrician.
Bell's palsy; Valtrex 1 gm po TID x 7 days; Prednisone Taper 60 mg, 40 mg, 20 mg po qDay x 10 days; Symptoms slowly improving
This spontaneous report as received from a health professional refers to a male patient of unknown age. On 05-AUG-2017 the patient was vaccinated with M-M-R II lot # N004433, 1 DF, subcutaneous for prophylaxis, reconstituted with sodium chloride (manufacturer unknown) lot # U5116AA (product preparation error). No adverse event reported.
Pt was given both vaccines in right arm ~one inch apart from each other. Pt started to verbalize that she was not feeling well or that she felt weird within 1-2 min of administration of vaccine. I offered pt water and a hard candy and recommended that she stay seated until episode passed. She then began to "faint" tilting forward. Her significant other and myself held her up in the seat so that she would not fall on the floor. The pt then proceeded to "tilt" her head back, "lock" up, and her face began to turn bright red as if she wasn't getting oxygen. I then grabbed for my EPIPEN thinking that it might be an allergic reaction to the vaccines, but did not administer because the pt started to "snap" out of her episode. My technician called 911 and the EMT arrived on the scene within 5 minutes of the call.
Provider ordered influenza vaccine 0.25 instead 0.5 FLUARIX was given.
Patient is a 85 y.o. male patient of a DO pmh copd, htn who presents to ED with cough and shortness of breath for the past 3 weeks   Acute deliriumresolved Alert awake oriented x 3 now Discussed with nursing staff to implement delirium precautions Continue clinical monitoring   Acute respiratory failure with hypoxia and hypercapnia, stable Acute exacerbation of copd>resolved Will need 2L O2 with activity Compelte decadron outpatient Pcp follow up   Covid-19 infection Date of onset of symptoms: 5/22/23 per patient Symptoms present on admission: cough, shortness of breath Date of covid positive test: 6/12/23 Vaccination status: fully vaccinated per patient Imaging: 6/12/23 CT without infi Imaging: 6/12/23 CT without infiltrates Oxygen requirements on admission: 2LNC Current oxygen requirements: 2 L nasal cannula Medical therapy: dexamethasone, ID consultedappreciate input.  Patient is not a candidate for remdesivir or Tocilizumab Consultants following: ID consulted Anticipated special isolation end date: 6/22   Essential htn Continue amlodipine    Iron deficiency anemia Started oral ferrous sulfate>continue  Seizure disorder  Continue phenytoin.    Cachexia Moderate protein-calorie malnutrition, POA Bmi 17.33 Continue oral nutritional supplementation   Left lung nodule Incidental findingnoted on CT Follow-up CT chest in 3 months
Nausea, diarrhea, chills, fever, body ache, vomiting
After receiving Menactra in her left arm, she immediately started with swelling and erythema around the Menactra injection.  I was called into the room by the medical assistant and patient was upset and crying that her arm hurt.  She had an approx. 4 inch diameter area of erythema around the injection site and it was swollen.  We immediately applied an ice pack.  Then a few minutes later, mom noted three small red macules on her right forehead and a splotchy red rash on her chest.  Her chest was clear, there were no respiratory symptoms, no mouth or facial swelling.  Vitals were stable the entire time.  She was given 300mg ibuprofen for the pain and 37.5mg benadryl for the rash.  Even before giving the benadryl, the chest rash disappeared and the forehead rash started to improve. Patient was observed for approx. 45-50 minute after the vaccine and rash, swelling, and pain had completely resolved prior to leaving the office.  Lungs were clear the entire time.
Patient received her flu vaccine at a local pharmacy. Approx 3 days following she developed pruritic hyperpigmented and slightly scaly papules and plaques on distal bilateral LE and a single lesion on her left mid arm. No other symptoms. Symptoms improved, but continue.
Information has been received on 13-APR-2018 regarding a case in litigation from a lawyer and a male consumer of unknown age. The patient's concurrent conditions, medical history and concomitant medications are unknown. On or about 04-APR-2012, the patient was inoculated with ZOSTAVAX (lot number and expiration unknown) unknown route, at a pharmacy as recommended for routine adult health maintenance and for the prevention of shingles. The vaccine did not prevent shingles as intended and the patient subsequently contracted a persistent strain of herpes zoster. On or about 14-JUN-2012, the patient was treated by a health care professional for a vesicular outbreak which was diagnosed as herpes zoster, or shingles. The patient has been prescribed LORTAB for management of her painful symptoms. As a direct and proximate result of the ZOSTAVAX, and/or despite receiving ZOSTAVAX for long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. Additional information has been requested.
Nearly passed out the following morning; headache; muscle aches; chills; fatigue; swollen and painful lymph nodes under left arm and collar bone; swollen and painful lymph nodes under left arm and collar bone; booster; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 45 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 16Dec2021 12:45 (Lot number: FL3197) at the age of 45 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "anxiety disorder" (unspecified if ongoing); "Acid reflux (oesophageal)" (unspecified if ongoing). Patient did not have known allergies. Concomitant medication(s) included: PROZAC; DEXILANT; CLARITINE, unspecified  birth control and unspecified vitamines. Vaccination history included: Bnt162b2 (Dose 2, Batch/Lot No: EP6955, in arm left), administration date: 12Apr2021, when the patient was 45 years old, for COVID-19 immunisation; Bnt162b2 (Dose 1, Batch/Lot No: EP6955, in arm left), administration date: 22Mar2021, when the patient was 45 years old, for COVID-19 immunisation. The following information was reported: LOSS OF CONSCIOUSNESS (medically significant) with onset 17Dec2021, outcome "recovering", described as "Nearly passed out the following morning"; HEADACHE (medically significant) with onset 17Dec2021, outcome "recovering", described as "headache"; MYALGIA (medically significant) with onset 17Dec2021, outcome "recovering", described as "muscle aches"; CHILLS (medically significant) with onset 17Dec2021, outcome "recovering", described as "chills"; FATIGUE (medically significant) with onset 17Dec2021, outcome "recovering", described as "fatigue"; LYMPH NODE PAIN (medically significant), LYMPHADENOPATHY (medically significant) all with onset 17Dec2021, outcome "recovering" and all described as "swollen and painful lymph nodes under left arm and collar bone"; IMMUNISATION (non-serious) with onset 16Dec2021 12:45, outcome "unknown", described as "booster". Therapeutic measures were not taken as a result of loss of consciousness, headache, myalgia, chills, fatigue, lymph node pain, lymphadenopathy. Additional information: the patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination the patient has not been diagnosed with COVID-19. Since the vaccination the patient has not been tested for COVID-19.  No follow-up attempts are possible. No further information is expected.
pt recvd vax & 3 to 4 hrs following vax pt had a large amount of swelling @ the inj site; which was also red, hard & hot;the nurse felt a concern about the particular lot of vax;pt recovered in approx 3 days;
76 y.o. female patient with history of osteoarthritis, sciatica. Presents with acute on chronic lower back pain. Found to be Covid positive on admission. Required NC O2, but likely due to CHF exacerbation and chronic underlying respiratory failure and less so actual covid infection. Required home O2 on discharge.    Acute on Chronic Respiratory Failure Hypercapnic with metabolic acidosis, likely 2/2 chronic respiratory failure contributed to by possible CHF exacerbation from Covid infection given pulmonary edema on CXR  May also have some contribution from possible OHS/OSA  Requiring 1L NC during stay Qualified for home O2 Recommend Sleep study as outpatient Consider PFT's outpatient    Covid Afebrile, VSS otherwise ID consulted - remdesivir and steroids Remdesivir discontinued due to AKI as below Stopped steroid course upon discharge as will only further increase her blood sugar levels    AKI on CKD, improved Cr 2.07 (b/l 2-2.37) on admission 2/2 remdesivir, discontinued   AKI improved upon discharge    Chronic HFpEF  BNP of 4725 on admission  TTE 3/2021 with EF 69%, grade I diastolic dysfunction CXR with pulmonary edema that improved with diuresis during stay  Can continue home lasix on discharge   Acute on chronic back pain Worsening chronic back pain refractory to home regimen- 3/3 Pain well controled Admission CT lumbar spine: multilevel degeneration, central spinal stenosis, no acute fractures or trauma noted  MRI 3/26/21: severe central spinal canal stenosis/narrowing L2-S1 MRI 2/25/23: severe DDD, marked disc bulge L5-S1 with disc protrusion and osteophytes deviated superiorly, thecal sac 7 mm at L5-S1 but only 5.4 mm at L4-L5 Home pain regimen: ASA, gabapentin Pain: tylenol, ASA, flexeril TID prn, lidocaine patches, oxy 5mg PRN q6H C/s neurosurgery, PMR- no acute intervention Consider PMR f/u outpatient    DMT2 Neuropathy  Glucose at goal, last A1c 4.9 Home regimen: lantus 15U daily Held insulin on admission given stable BG However, elevation of BG day of DC due steroid use; 10u lispro given prior to DC Given A1c 4.9 and stopping steroids on discharge, will discontinue home lantus regimen on discharge    Dysphagia Patient reports dysphagia recently when trying to swallow some of her pills, no other related symptoms Passed bedside swallow Monitored    Microcytic Anemia Admission Hgb 8.7 (b/l 8-10), MCV 76.9, Hgb now stable in 7s Likely 2/2 CKD  Fe 28, TIBC 138, ferritin 474 Administered IV iron per KDIGO guidelines Resumed oral iron at discharge   Hypertension Chronic, remains elevated, likely contributed to by pain Home meds: amlodipine continued Home carvedilol 25 mg nightly held briefly for bradycardia Resumed carvedilol at 12.5 mg BID     Lymphedema Chronic, at baseline Continued Home regimen: lasix 20 mg daily  Concern for OSA/OHS Required 1L NC as above  Recommend Sleep Study outpatient
This spontaneous report was received from a 51 year old female patient, who was reporting on herself. The patient's pertinent medical history, drug reactions or allergies and concomitant medications were not reported. On an unknown date in July 2015, the patient was subcutaneously vaccinated with a dose of ZOSTAVAX injection (site of administration, dose, lot number and expiration date were not reported). On an unknown date in 2015 (reported as the next day), the patient "had a reaction". She stated that her arm became itchy and red, which later (on an unspecified date in 2015) changed to a large itchy lump that made her arm look as though she had "an extra muscle in her arm". A few days later (on an unspecified date in 2015), the patient called and visited her physician, who stated that she had a "septic reaction" to the ZOSTAVAX injection. The physician treated the patient with unspecified antibiotics and "her arm cleared up in a few days". The outcome of the event was reported as recovered on an unknown date in approximately 2015. The reporter considered "septic reaction" to be related to vaccination with ZOSTAVAX. Upon internal review, "septic reaction" to the ZOSTAVAX injection was determined to be medically significant. Additional information has been requested.
Got the last shingrix on 9/13/2021 the 1st on 4/25/2021. Around 1am on 9/14/2021 less than 24 hours a red rash begin around my navel area and my right leg and it kept growing every day until a 80% of my body was covered in a red rash and some blisters. Went to an urgent care and the PA thought maybe shingles not sure. Went to the ER around 10pm on 9/19/2021 and got a steroled shot and a prescription for predinsone in which I am still taking to my 3rd prescription. My dermatologist also prescribe Triamcinolone Acetonide Cream USP. 0.1%.
A 53 year old female with a history of fibromyalgia and chronic fatigue syndromes reported that she received a booster dose of tetanus toxoid adsorbed, purogenated on 01/06/2001. On 01/07/2001, she developed a fever and pain at the injection site. She was treated wtih aspirin and naproxen sodium. The reporter declined to provide additional info and declined to grant permission for follow-up investigation.
2 weeks following shot: Arms feel heavy and strange, "buzzing behind knees, wrists", palpitations, residual left upper and lower extremities feelings of weakness, quivering voice, shaky legs, hands cramping.
Client received DTaP and Hep A vaccines at PHO 6/30/04 and within 20 min c/o hives, N/V, wheezing, Benadryl 40mg IM and Epi. 20cc given per Emergency Protocol.  Nurse follow up on 07/13/04 states: "No new information."  Nurse follow up on 07/19/04 states: "Shortness of breath."
Tachycardia 170 bpm for 2 days post 1st dose; This case was reported by a pharmacist via call center representative and described the occurrence of tachycardia in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced tachycardia. On an unknown date, the outcome of the tachycardia was unknown.   It was unknown if the reporter considered the tachycardia to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient received Shingrix and experienced tachycardia 170 bpm for 2 days. No additional information was provided. The reporter did not consent to follow up.
Headache, Myalgia, Arthralgia & NauseaVomiting Narrative:  Is taking Ibuprofen/ Advil, also took Zofran for nausea. Body aches are 10/10, sometimes improve down to 8/10.
Dermatologist diagnosed new rash as pityriseas rosea cuased by a virus.
2 days after vaccine administered developed a rash on the (R) shoulder (the following day also developed a local spot of erythema 4 inch diameter at the injection site). 5 days later still with shoulder rash. Is not vesicular in appearance, does not follow dermatome.
She was 'bouncing off the walls'.; unsteadiness; Nausea; extreme dizziness; fatigue/bad enough that for 3 days she couldn't work; This is spontaneous report received from Pfizer Sponsored Program Support from a contactable consumer (patient). This 68-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), dose 1 via an unspecified route of administration, administered in upper left arm on 15Mar2021 09:30 (Lot Number: EN6207) as single dose for COVID-19 immunization.  The patient's medical history and concomitant medications were none.  The patient experienced nausea on 15Mar2021 18:00, extreme dizziness on 15Mar2021 18:00, fatigue/bad enough that for 3 days she couldn't work on 15Mar2021 18:00, she was 'bouncing off the walls' on an unspecified date, unsteadiness on an unspecified date. She went on 15Mar2021 to get her first shot and then she was went for her second vaccine this past Saturday. Patient stated they denied giving her the 2nd dose of the covid vaccine after hearing about her side effects form the 1st one. She would like to know whether she needs to get the 2nd dose. She had pretty bad reactions to the first shot. She got the shot around 09:30 in the morning and by 6 pm she felt the reactions. Patient reported the following side effects form the 1st dose of the covid vaccine: nausea, extreme dizziness and fatigue, bad enough that for 3 days she couldn't work. She was 'bouncing off the walls', unsteadiness and spent the next three days in bed due to fatigue. There was no event require a visit to emergency room and physician office. There was no prior vaccination (within 4 weeks) and no adverse event following prior vaccinations. The outcome of event nausea was recovered on 16Mar2021, extreme dizziness and fatigue/bad enough that for 3 days she couldn't work was recovered on 18Mar2021, She was 'bouncing off the walls' was recovered on an unspecified date, unsteadiness was unknown.  No follow-up attempts are possible. No further information is expected.
The morning after receiving the Influenza and Prevnar vaccines she developed a fever (101.7 and above), chills, and headache associated with diarrhea. Soreness of the right arm greater than left was also reported. Physical exam noted mild dime-sized erythema at the right deltoid injection site. She denied a lumbar puncture for meningeal workup. She was treated with Tylenol and an outpatient course of Keflex for 7 days due to questionable cellulitis of the arm.
This spontaneous report as received from a registered nurse refers to a patient of an unknown age and gender. There was no information about the patient's concurrent conditions, medical history, any known allergies or reactions or concomitant medications. On an unknown date in 2016 (reported as between May2016 and December 2016), the patient was vaccinated with improperly stored VARIVAX lot # L021214 with expiration date of 10-JUN-2017, for prophylaxis (dose and route of administration were not reported), reconstituted with properly stored sterile diluent (dose, route of administration, lot number and expiration date were not reported). The vaccine was exposed to a temperature excursion of 15-46 degrees Fahrenheit (°F) for 12 hours. There were previous excursions of 15-46 degrees Fahrenheit (°F) for 29 hours.  There was not data logger involved. No adverse symptoms were reported. No product quality complaint was involved. No further information was provided. This is one of several reports received from the same reporter. Additional information has been requested. Sender's Comments: US-009507513-1705USA001690: US-009507513-1705USA001693.
Swollen and painful kidneys that started about 36 hours after shot.  Very painful for 3 days before getting better but still tender.
Paralysis for over 1yr, acute inflammation, muscle structure damage resulting in heart surgery, continuing issues. Still not resolved.
No AE/PQC.; V AQT A was administered after it's expiration date; This spontaneous report as received from an office manager referring to a patient of unknown age and gender. Information regarding the patient's pertinent medical history, current condition, drug reactions/allergies and concomitant medication were not provided.         On 22-JUL-2021, the patient was vaccinated with expired hepatitis a vaccine, inactivated (VAQTA) (1 ml, strength, route of administration and anatomical site of vaccination were not reported, lot # T018670, expiration date reported as 11-JUL-2021) for prophylaxis (expired product administered). The outcome of expired product administered was unknown. The vaccine had no prior temperature excursions. No additional adverse events reported.
Gradually I noticed that I was experiencing short term memory loss (which I had never experienced before). Sometimes I will forget what I do 5 min ago and its so frustrating. This does not run in my family. Also, I am more susceptible to viruses and its taking me much longer to get over them. I used to be extremely healthy and an exercise fanatic but now I feel exhausted and worn out.
Initial report was received on 16 December 2011 from an electronic lay press article. It represents a cluster of two patients reported by the same reporter who each experienced pertussis following vaccination with a pertussis vaccine (manufacturer not reported). The second patient is captured in case number 2011-12375. A 10-year-old patient (gender not reported) had received an injection of pertussis vaccine (manufacturer, lot number, route, site and date of administration not reported) and an unspecified amount of time later, developed pertussis. The patient was reported as up-to-date with immunizations. No further information was available at the time of the report. The patient's outcome was not reported. Documents held by sender: none.
This spontaneous report as received from an other health professional (Registered Nurse) refers to patients of unknown age and demographics. Current conditions and medical history was not reported. On 07-OCT-2014, the patient was vaccinated with VARIVAX (Merck) injection, subcutaneous (dose and frequency was not reported). Concomitant medications were not reported. It was reported that doses of improperly stored VARIVAX (Merck) was administered to unspecified patients on 07-OCT-2014. This was supported. No adverse effects reported. Product quality complaint was not reported. This case is linked to 1410USA005725 (same reporter). Additional information has been requested.
OUT OF SPECIFICATION USE (VACCINE ADMINISTERED 1 DAY AFTER OPENED); This spontaneous report received from a health care professional concerned a 64 year old female. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 201A21A, expiry: 23-JUN-2021) dose was not reported, administered on 22-JUN-2021 for prophylactic vaccination. No concomitant medications were reported. On 22-JUN-2021, the subject experienced out of specification use (vaccine administered 1 day after opened). The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of out of specification use (vaccine administered 1 day after opened) was not reported. This report was non-serious.
Rash left upper outer thigh with 9 x 14 cm of mild erythema with a central area with mild induration about 4 x 4 cm with the punctate lesion in the superior central region. Right thigh with 12 x 15 mm of erythema with a central punctate lesion.
pt recvd vax; c/o hand & wrist "feels funny,different" that noc & next am; sxs cleared in 48-72 hrs & hand felt nl;